Abstract
Background: Multidrug-resistant Escherichia coli, especially a lineage of O25b:H4-ST131, has increased and spread worldwide. The surveillance of cross-resistance of E. coli is necessary. Methods: Cross-resistance to fluoroquinolones (FQs) and aminoglycosides (AGs) was examined in E. coli isolated in Hokkaido Prefecture, Japan, between 2008 and 2009. Results: Gentamicin (GEN) resistance was more common in FQ-resistant isolates (30/112 strains; 26.8%) than in FQ-susceptible isolates (2/100 strains; 2%). The frequency of GEN resistance was similar in two groups of FQ-resistant strains, O25b:H4-ST131 genotype (22/87 strains; 25.3%) and a group of other FQ-resistant genotypes (8/25 strains; 32.0%). The main AG resistance gene was aac(3)-II (87.5% of GEN-resistant strains). The only amikacin-resistant strain which was FQ resistant carried the aac(6')-Ib-cr gene. CTX-M type extended-spectrum β-lactamase (ESBL) genes were also found in FQ-resistant strains at a high frequency. However, the number of strains with both ESBL and AG-modifying enzyme genes was relatively low (8 strains). Conclusion: All FQ-resistant strains, not only O25b:H4-ST131, appeared to preferentially acquire ESBL genes and/or genes encoding AG-modifying enzymes; however, the acquisitions of these genes seemed to occur independently.
Journal Section:
Editor's choice
References
1.
Kaper JB, Nataro JP, Mobley HL: Pathogenic Escherichia coli. Nat Rev Microbiol 2004;2:123-140.
[PubMed]
2.
Mandell GL, Douglas RG, Bennett JE, Dolin R: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, ed 6. New York, Churchill Livingstone, 2005.
3.
Foxman B: The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653-660.
[PubMed]
4.
Schaeffer A: Infections of the urinary tract; in Wein A, Kavoussi L, Novick A, Partin AW, Peters CA (eds): Campbell-Walsh Urology, ed 9. Philadelphia, Saunders Elsevier, 2007, pp 223-303.
5.
Hayami H, Takahashi S, Ishikawa K, et al: Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother 2013;19:393-403.
[PubMed]
6.
Pitout JD, Laupland KB: Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
[PubMed]
7.
Falagas ME, Karageorgopoulos DE: Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 2009;73:345-354.
[PubMed]
8.
Pitout JD: Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev Anti Infect Ther 2012;10:1165-1176.
[PubMed]
9.
Lynch JP 3rd, Clark NM, Zhanel GG: Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opin Pharmacother 2013;14:199-210.
[PubMed]
10.
Woodford N, Turton JF, Livermore DM: Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35:736-755.
[PubMed]
11.
Peirano G, Pitout JD: Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010;35:316-321.
[PubMed]
12.
Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, Park YJ, Lavigne JP, Pitout J, Johnson JR: Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;61:273-281.
[PubMed]
13.
Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Canton R, Nordmann P: Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis 2008;14:195-200.
[PubMed]
14.
Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y: Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009;63:72-79.
[PubMed]
15.
Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N: Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan. Chemotherapy 2012;58:52-59.
[PubMed]
16.
Yano H, Uemura M, Endo S, Kanamori H, Inomata S, Kakuta R, Ichimura S, Ogawa M, Shimojima M, Ishibashi N, Aoyagi T, Hatta M, Gu Y, Yamada M, Tokuda K, Kunishima H, Kitagawa M, Hirakata Y, Kaku M: Molecular characteristics of extended-spectrum β-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS One 2013;8:e64359.
[PubMed]
17.
Guiral E, Bosch J, Vila J, Soto SM: Antimicrobial resistance of Escherichia coli strains causing neonatal sepsis between 1998 and 2008. Chemotherapy 2012;58:123-128.
[PubMed]
18.
Ho P-L, Chen VCC: Epidemiology and mechanisms of resistance; in Ronald AR, Low DE (eds): Fluoroquinolone Antibiotics. Basel, Birkhauser, 2003, pp 49-71.
19.
Walsh C: Enzymatic destruction or modification of the antimicrobial bacteria; in Walsh C (ed): Antibiotics: Actions, Origins, Resistance. Washington, American Society for Microbiology, 2003, pp 106-123.
20.
Jana S, Deb JK: Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006;70:140-150.
[PubMed]
21.
Vakulenko SB, Mobashery S: Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003;16:430-450.
[PubMed]
22.
Shaw KJ, Rather PN, Hare RS, Miller GH: Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993;57:138-163.
[PubMed]
23.
Shakya T, Wright GD: Mechanisms of aminoglycoside antibiotic resistance; in Arya DP (ed): Aminoglycoside Antibiotics: from Chemical Biology to Drug Discovery. Hoboken, John Wiely & Sons, 2007, pp 119-140.
24.
Wachino J, Arakawa Y: Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012;15:133-148.
[PubMed]
25.
Magnet S, Blanchard JS: Molecular insights into aminoglycoside action and resistance. Chem Rev 2005;105:477-498.
[PubMed]
26.
Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 8th edition. CLSI document M07-A8. Wayne, CLSI, 2009.
27.
Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement, M100-S20. Wayne, CLSI, 2010.
28.
van de Klundert JAM, Vliegenthart JS: PCR detection of genes coding for aminoglycoside-modifying enzymes; in Persing DH, Smith TF, Tenover FC, White TJ (eds): Diagnosstic Molecular Microbiology. Washington, American Society for Microbiology, 1993, pp 547-552.
29.
Sandvang D, Aarestrup FM: Characterization of aminoglycoside resistance genes and class 1 integrons in porcine and bovine gentamicin-resistant Escherichia coli. Microb Drug Resist 2000;6:19-27.
[PubMed]
30.
Hu X, Xu B, Yang Y, Liu D, Yang M, Wang J, Shen H, Zhou X, Ma X: A high throughput multiplex PCR assay for simultaneous detection of seven aminoglycoside-resistance genes in Enterobacteriaceae. BMC Microbiol 2013;13:58.
[PubMed]
31.
Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC: Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006;50:3953-3955.
[PubMed]
32.
Okubo T, Sato T, Yokota S, Usui M, Tamura Y: Comparison of broad-spectrum cepharosporin-resistant Escherichia coli isolated from dogs and humans in Hokkaido, Japan. J Infect Chemother 2014;20:243-249.
[PubMed]
33.
Sato T, Yokota S, Okubo T, Usui M, Fujii N, Tamura Y: Phylogenetic association of fluoroquinolone and cephalosporin resistance of D-O1-ST648 Escherichia coli carrying blaCMY-2 from faecal samples of dogs in Japan. J Med Microbiol 2014;63:263-270.
[PubMed]
34.
Clermont O, Johnson JR, Menard M, Denamur E: Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 2007;57:129-136.
[PubMed]
35.
Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;12:83-88.
[PubMed]
36.
Wieler LH, Ewers C, Guenther S, Walther B, Lubke-Becker A: Methicillin-resistant staphylococci (MRS) and extended-spectrum β-lactamases (ESBL)-producing Enterobacteriaceae in companion animals: nosocomial infections as one reason for the rising prevalence of thesepotential zoonotic pathogens in clinical samples. Int J Med Microbiol 2011;301:635-641.
[PubMed]
37.
Schink AK, Kadlec K, Kaspar H, Mankertz J, Schwarz S: Analysis of extended-spectrum-β-lactamase-producing Escherichia coli isolates collected in the GERM-Vet monitoring programme. J Antimicrob Chemother 2013;68:1741-1749.
[PubMed]
38.
Guenther S, Aschenbrenner K, Stamm I, Bethe A, Semmler T, Stubbe A, Stubbe M, Batsajkhan N, Glupczynski Y, Wieler LH, Ewers C: Comparable high rates of extended-spectrum-β-lactamase-producing Escherichia coli in birds of prey from Germany and Mongolia. PLoS One 2012;7:e53039.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
